PHAR$18.16
$18.29
Chart
Performance
Key Stats
AI PHAR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyPharming Group demonstrates a mixed profile with strong fundamental indicators, particularly in its financial health and growth potential, but faces some headwinds in its current valuation and technical indicators. The company's focus on rare diseases and its product pipeline provide a solid thematic foundation.
Thematic
Pharming Group is positioned in the niche but growing biopharmaceutical sector, focusing on rare diseases. Its pipeline, including OTL-105 for HAE, indicates a targeted approach to high-need medical areas. The company's collaborations suggest strategic partnerships for growth.
Fundamental
Pharming Group exhibits a strong balance sheet with manageable debt levels and positive cash reserves. Revenue has shown growth, although the company is currently experiencing net losses. Profitability metrics need to improve for a higher score.
Technical
The stock is trading within its 52-week range, with recent price action showing some upward momentum. However, technical indicators like RSI and MACD suggest mixed signals, with potential for consolidation.
| Factor | Score |
|---|---|
| Rare Disease Focus | 85 |
| Biopharmaceutical Innovation | 70 |
| Strategic Partnerships | 75 |
| Market Size and Growth | 80 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 55 |
| Growth | 80 |
| Balance Sheet Health | 85 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 65 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Support & Resistance | 70 |
| Technical Indicators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong 1-Year Performance
The stock has shown a significant positive performance of 22.44% over the last year, outperforming the broader market.
Positive Moving Averages
Multiple moving averages (10-day, 20-day, 100-day, 200-day) are indicating 'Buy' signals on the 1h timeframe, suggesting upward momentum.
Bearish Points (8)
Recent Net Losses
The company has reported net losses in the most recent annual periods (2024: -$11.84M, 2023: -$10.55M), indicating profitability challenges.
Negative Earnings Per Share (EPS)
The EPS TTM is reported as -0.21, and the company has experienced net losses in recent years, suggesting that current valuation multiples based on earnings are not meaningful.
Calendar
July 2025
31
Next Earnings Date
H: $0.00
A: $-0.01
L: $-0.03
H: 70.90M
A: 70.36M
L: 69.82M
Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Seasonals
Price Target
30.33 USD
The 39 analysts offering 1 year price forecasts for PHAR have a max estimate of 40.00 and a min estimate of 14.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Major diversified healthcare company with a large, innovative pharmaceutical division focused on various therapeutic areas.
Weight: 97
One of the world's largest pharmaceutical companies, engaged in the discovery, development, manufacturing, and marketing of prescription medicines and vaccines.
Weight: 96
Global pharmaceutical company with a strong focus on prescription medicines, vaccines, and animal health products, including leading oncology therapies.
Weight: 95
Research-based pharmaceutical company developing treatments for a wide range of conditions, notably diabetes, obesity, oncology, and neuroscience.